Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Neurocrine Biosciences | Other Grant/Funding Number | Neurocrine Biosciences |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Neurocrine Biosciences | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.
Study Purpose and Rationale
Congenital adrenal hyperplasia (CAH) is a complex, lifelong endocrine disorder that requires continuous glucocorticoid replacement, stress-dosing during illness, and ongoing monitoring for metabolic, reproductive, and adrenal complications. Adolescents and young adults face substantial challenges maintaining these self-management responsibilities during the transition from pediatric to adult care, a period consistently associated with decreased adherence, reduced clinic attendance, lapses in emergency preparedness, and preventable adrenal crises. Despite these risks, there are currently no structured, evidence-informed transition programs tailored specifically to the needs of individuals with CAH.
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary impact of implementing the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with CAH. By combining structured education, readiness assessment, emergency preparedness training, and coordinated transfer to adult endocrinology, this mixed-methods pilot aims to strengthen self-management skills, improve continuity of care, and reduce acute health events. Findings will inform refinement of the CAH-T model and provide essential pilot data needed to support future multi-site implementation.
Objectives and Hypotheses
The overall objective of this mixed-methods feasibility study is to evaluate the implementation and preliminary effectiveness of the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study aims to determine whether the intervention can be feasibly delivered in a pediatric endocrine clinic, is acceptable to patients and caregivers, and produces early improvements in transition-related outcomes.
The investigators hypothesize that.
Study Design Overview This is a prospective, single-center, single-arm, mixed-methods feasibility and implementation study conducted over 24 months. Adolescents and young adults aged 16-20 years with a diagnosis of CAH, along with one of their caregivers, will participate in a structured transition curriculum integrated into routine endocrine visits. Quantitative measures of readiness, knowledge, quality of life, and emergency preparedness will be collected at baseline, post-intervention, and at 12-month follow-up. Semi-structured interviews with adolescents, caregivers, and providers will be used to contextualize quantitative findings and identify implementation barriers and facilitators.
Population and Sample Size Summary
The study will enroll approximately 15 adolescents and young adults with CAH (ages 16 years and older) and one caregiver per participant from the Children's Hospital of Alabama pediatric endocrinology clinic. This sample size is appropriate for feasibility pilot work in a rare disease population and will provide sufficient data to estimate feasibility metrics, evaluate acceptability, and generate preliminary effect-size estimates for future multi-site trials.
Primary and Secondary Outcomes
Primary Outcomes
Feasibility:
Acceptability: ≥80% of participants and caregivers rate the program "satisfied/very satisfied" at their 12-month follow-up
Secondary Outcomes
Transition Readiness: ≥10% improvement in STARx/STARx-P scores at the 12 month follow-up compared to a baseline score.
CAH-Specific Knowledge: ≥10% improvement in CAHKAQ scores at the 12 month follow-up compared to a baseline score.
Emergency Preparedness:
Health-Related Quality of Life: ≤10% change in CAHQL scores over 12 months
Transfer Outcomes: ≥80% of eligible participants attend at least one adult endocrinology visit within 6 months post-transfer
Acute Care Utilization: Stable or reduced emergency/urgent care visits pre- vs. post-intervention
Brief Procedures Summary
Participants will complete a baseline assessment including demographics, CAH knowledge (CAHKAQ),9 transition readiness (STARx/STARx-P),10-12 emergency preparedness, and quality-of-life measures (CAHQL).13 They will then participate in two CAH-T curriculum14 visits embedded in routine endocrine appointments. Age-eligible participants (over 18 years old) will be transferred to adult care following completion of the curriculum and monitored for completion of an adult endocrinology visit. All participants will complete a 12-month follow-up assessment, and emergency care utilization will be recorded for the year preceding enrollment and for the year following intervention completion. Semi-structured interviews will be conducted with adolescents, caregivers, and providers after the program's implementation to explore perceptions of the program's feasibility and acceptability.
Significance / expected impact This study aims to address a significant gap in endocrine transitional care by piloting the first structured, CAH-specific transition program at a U.S. pediatric center. The implementation of CAH-T is expected to improve self-management skills, enhance preparedness for adrenal crises, support a stable quality of life, and increase successful connection to adult endocrinology care. Findings will generate foundational evidence needed to refine the intervention and support future multi-site trials aimed at establishing best practices for transition in rare endocrine disorders.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| adolescent and young adult with congenital adrenal hyperplasia |
| ||
| guardian/caregiver of adolescent/young adult with congenital adrenal hyperplasia |
| ||
| clinical provider of patients with congenital adrenal hyperplasia |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| exposure to healthcare transition protocol | Other | CAH-T Curriculum Visits CAH-T Visit 1 (V1) CAH-T Visit 1 will occur approximately 3 months after enrollment and will include:
For participants aged ≥18 years:
CAH-T Visit 2 will occur approximately 6 months after enrollment and will include:
|
| Measure | Description | Time Frame |
|---|---|---|
| assessment of CAH knowledge | Brief survey of CAH knowledge with Congenital adrenal hyperplasia knowledge questionnaire looking at the treatment of the condition and the mechanism of congenital adrenal hyperplasia. Minimum score 0; Maximum score 44; with 0 indicating lack of knowledge of CAH | at baseline, 6 months, and 12 month after initiation of healthcare transition readiness |
| Self-Management and Transition to Adulthood with Rx (Self-Management and Transition to Adulthood with Rx-parent) questionnaire regarding transtion readiness | This questionnaire assesses patient's readiness for movement to adult healthcare. minimum score of 0, maximum score of 90. 0 indicating patient is not ready for movement to the adult healthcare system. | at baseline, 6 months and after 12 month visit |
| Change in quality of life for patients with CAH | assessment of CAH quality of life with questionnaire (CAHQL). Scale from 0-100 with increasing scale indicating a higher quality of life. | at baseline, and 6 and 12 month follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| number of participants that receive the emergency preparedness checklist | checklist to understand patient understanding of preparing for adrenal crisis | baseline, 6 months, and 12 months after initiation of transition protocol |
| number of visits a participant requires for acute care |
Not provided
Inclusion Criteria:
YA Participants
Exclusion Criteria:
Not provided
Not provided
Not provided
This population will be recruited from our pediatric endocrinology clinic as available.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christy Foster, MD | Contact | 205-638-9107 | cafoster@uabmc.edu | |
| Leslie Pitts, PHD | Contact | lesliepitts@uab.edu |
| Name | Affiliation | Role |
|---|---|---|
| Christy Foster, MD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000312 | Adrenal Hyperplasia, Congenital |
| ID | Term |
|---|---|
| D047808 | Adrenogenital Syndrome |
| D012734 | Disorders of Sex Development |
| D014564 | Urogenital Abnormalities |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
review of patient's use of acute care for adrenal insufficiency. We will count the number of times a participant has to use an ER or urgent care clinic within a 6 month time frame (inquiring at baseline, 6 month, and 12 month visit) |
| baseline, 6 months and 12 months after initiation of healthcare transition protocol |
| Assess satisfaction and experience survey | assessment of satisfaction and experience survey. 5 question survey of Likert scale ranging 1-5 with 5 indicating very satisfied. | after completion of 12 month visit of health care transition protocol |
| themes regarding CAH healthcare transition | themes from focus groups from adolescents and young adults with CAH guardians/caregivers, and providers | up to 24 months |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D030342 | Genetic Diseases, Inborn |
| D043202 | Steroid Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |